Regulatory update removes outdated U.S.–EU inspection framework while maintaining current international cooperation practices
The U.S. Food and Drug Administration (FDA) has issued a final rule revoking certain regulations related to the mutual recognition of pharmaceutical Good Manufacturing Practice (GMP) inspection reports and medical device quality system audit reports between the United States and the European Union.
The rule removes 21 CFR Part 26, titled Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports, effective March 23, 2026.
Why FDA Is Removing These Regulations
The regulations were originally implemented to support a 1998 Mutual Recognition Agreement (MRA) between the U.S. and the European Community. Since that time, international regulatory cooperation has evolved significantly.
FDA determined the regulations are now outdated and unnecessary because:
- Portions have been replaced by updated U.S.–EU agreements
- Some provisions were never fully implemented
- Current regulatory practices operate outside the framework of these legacy rules
Removing the regulations aligns the Code of Federal Regulations with how mutual recognition arrangements are currently administered.
What This Means for Importers
For most pharmaceutical and medical device importers, the practical impact is expected to be minimal.
The revocation does not eliminate mutual recognition arrangements themselves, and FDA continues to rely on international regulatory cooperation to support inspection oversight and product safety.
Importers should expect:
- No new compliance requirements
- No new costs or reporting obligations
- Continued reliance on existing GMP and quality system standards
However, companies should continue maintaining appropriate documentation demonstrating compliance with applicable manufacturing and regulatory requirements.
Compliance Considerations
While the change is primarily administrative, importers should ensure:
- Supplier qualification and GMP documentation remain current
- Inspection and compliance records are properly maintained
- Internal procedures reference current regulatory frameworks rather than legacy provisions
Regulatory modernization efforts like this are intended to streamline oversight while maintaining safety standards, but they can still affect how compliance programs are structured.
How Alba Can Help
Alba’s regulatory specialists monitor FDA developments impacting pharmaceutical, life sciences, and medical device imports. If you have questions about documentation, supplier compliance, or import procedures, our team can help ensure your shipments remain compliant and move efficiently.
